君实生物偌考奇拜单抗注射液新药上市申请获受理

Core Viewpoint - Junshi Biosciences has received the acceptance notice from the National Medical Products Administration for the new drug application of Rocabotamab injection for the treatment of moderate to severe plaque psoriasis in adult patients suitable for systemic therapy or phototherapy [1] Group 1 - The drug Rocabotamab is a specific anti-IL-17A monoclonal antibody that binds with high affinity to IL-17A and selectively blocks its interaction with receptors IL-17RA/IL-17RC [1] - By inhibiting the activation of downstream signaling pathways and the release of inflammatory factors, Rocabotamab can effectively alleviate symptoms of autoimmune diseases [1]